# Pulse Biosciences, Inc.: overview PLSE · Nasdaq · CIK 1625101 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/plse.md) · [Financials](/companies/plse/financials.md) · [Filings](/companies/plse/filings.md) · [Insiders](/companies/plse/insiders.md) Latest reported revenue: [$434.0k](/filings/0001437749-26-026288.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 6, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001437749-26-026288). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [0.0](/filings/0001437749-25-033354.md) | [0.0 d](/filings/0001437749-26-004724.md) | [0.0](/filings/0001437749-26-016897.md) | [0.0](/filings/0001437749-26-026288.md) | [0.1](/filings/0001437749-25-033354.md) | [0.3 d](/filings/0001437749-26-004724.md) | [0.4](/filings/0001437749-26-016897.md) | [0.4](/filings/0001437749-26-026288.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | [(23682.6%)](/filings/0001437749-25-033354.md) | [(6914.0%) d](/filings/0001437749-26-004724.md) | [(4775.6%)](/filings/0001437749-26-016897.md) | [(5823.0%)](/filings/0001437749-26-026288.md) | | Net margin | % | not reported | not reported | not reported | not reported | [(22540.7%)](/filings/0001437749-25-033354.md) | [(6603.4%) d](/filings/0001437749-26-004724.md) | [(4633.7%)](/filings/0001437749-26-026288.md) | [(5681.3%)](/filings/0001437749-26-026288.md) | | Diluted EPS | $ per share | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Free cash flow | $m | [(9.1) d](/filings/0001437749-25-033354.md) | [(9.2) d](/filings/0001437749-26-004724.md) | [(13.6)](/filings/0001437749-26-016897.md) | [(12.9) d](/filings/0001437749-26-026288.md) | [(13.1) d](/filings/0001437749-25-033354.md) | [(14.9) d](/filings/0001437749-26-004724.md) | [(14.6)](/filings/0001437749-26-016897.md) | [(18.8) d](/filings/0001437749-26-026288.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL not reported. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [1.4](/filings/0001437749-23-008846.md) | [0.7](/filings/0001437749-24-009815.md) | [0.0](/filings/0001437749-25-009932.md) | [0.0](/filings/0001437749-26-004724.md) | [0.4](/filings/0001437749-26-004724.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(4443.9%)](/filings/0001437749-23-008846.md) | [(8293.9%)](/filings/0001437749-24-009815.md) | not reported | not reported | [(21982.6%)](/filings/0001437749-26-004724.md) | | Net margin | % | [(4489.4%)](/filings/0001437749-23-008846.md) | [(8357.9%)](/filings/0001437749-24-009815.md) | not reported | not reported | [(20794.6%)](/filings/0001437749-26-004724.md) | | Diluted EPS | $ per share | [(2.28)](/filings/0001625101-22-000016.md) | not reported | not reported | not reported | not reported | | Free cash flow | $m | [(54.5)](/filings/0001437749-23-008846.md) | [(47.4)](/filings/0001437749-24-009815.md) | [(33.2)](/filings/0001437749-25-009932.md) | [(36.5)](/filings/0001437749-26-004724.md) | [(54.4)](/filings/0001437749-26-004724.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareBasicAndDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/plse/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $40.7m | 1,466,702 | | Added +126,924 | | [BANK OF AMERICA CORP /DE/](/funds/70858.md) | 2026-06-30 | $40.1m | 1,446,611 | | Added +580,550 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $21.9m | 788,640 | | Reduced −27,212 | | [Portolan Capital Management, LLC](/funds/1350290.md) | 2026-06-30 | $20.9m | 753,333 | | Added +19,961 | | [Balyasny Asset Management L.P.](/funds/1218710.md) | 2026-06-30 | $19.9m | 718,103 | | Added +452,939 | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $17.4m | 626,514 | | Added +484,364 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $14.9m | 536,276 | | Added +44,330 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $14.7m | 529,624 | | Added +72,697 | | [MASSACHUSETTS FINANCIAL SERVICES CO /MA/](/funds/912938.md) | 2026-06-30 | $12.8m | 462,734 | | Reduced −165 | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $7.6m | 275,669 | | Added +241,715 | ## Recent filings [All 639 filings](/companies/plse/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-14 | 12:43 ET | [8-K](/filings/0001437749-26-032601.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-26-032601 | | 2026-10-07 | 13:06 ET | [8-K](/filings/0001437749-26-032271.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-26-032271 | | 2026-09-15 | 20:44 ET | [8-K](/filings/0001437749-26-030456.md) | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 9.01 Financial statements and exhibits | 0001437749-26-030456 | | 2026-09-15 | 12:54 ET | [8-K](/filings/0001437749-26-030392.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-26-030392 | | 2026-08-06 | 21:04 ET | [8-K](/filings/0001437749-26-026351.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001437749-26-026351 | | 2026-08-06 | 20:23 ET | [10-Q](/filings/0001437749-26-026288.md) | Quarterly report, period 2026-06-30 | 0001437749-26-026288 | | 2026-08-06 | 20:06 ET | [8-K](/filings/0001437749-26-026256.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001437749-26-026256 | | 2026-07-29 | 13:01 ET | [8-K](/filings/0001437749-26-024758.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-26-024758 | | 2026-06-12 | 20:05 ET | [8-K](/filings/0001437749-26-020464.md) | 5.07 Shareholder vote results | 0001437749-26-020464 | | 2026-06-10 | 12:55 ET | [8-K](/filings/0001437749-26-020085.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-26-020085 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001437749-26-004724.md), filed Feb 19, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/349ee4f9-3be2-41cc-a33d-9933281d45de) ## About the filer - CIK: 1625101 - Tickers: PLSE - Exchange: Nasdaq - SIC code: 3841 Surgical & Medical Instruments & Apparatus - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:44 ET. No prices; not investment advice.